New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
16:17 EDTJNJ, PCYCPharmacyclics says $60M Janssen milestone payment to be recognized in Q3
As previously announced on July 28, that the FDA granted IMBRUVICA regular approval for the treatment of patients with CLL who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17, including treatment naive and previously treated del 17p CLL patients. This approval of IMBRUVICA in del 17p CLL triggers $60M in milestone payments to Pharmacyclics (PCYC) under its agreement with Janssen (JNJ), which will be recognized as revenue in the third quarter of 2014. To date, in addition to the upfront payment of $150M, Pharmacyclics has earned milestone payments of $505M under the agreement. It may receive up to an additional $320M in development, regulatory and approval milestone payments, however, clinical development entails risks and the company has no assurance as to whether or when the milestone targets might be achieved.
News For PCYC;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
12:17 EDTJNJMedivation plummets after Cowen highlights slowing Xtandi trends
Subscribe for More Information
11:23 EDTJNJMedivir says Janssen's Alios BIopharma starts Phase I AL-704 trial
Subscribe for More Information
July 28, 2015
07:05 EDTJNJMacroGenics reports MGD011 advances into clinical development
Subscribe for More Information
July 27, 2015
10:40 EDTJNJLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
July 23, 2015
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
July 22, 2015
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use